Excited to share our systematic review and meta-analysis of standard- versus reduced-dose sotorasib in KRAS G12C-mutated NSCLC, now published in @JCOOP_ASCO Reduced dosing did not appear to substantially compromise efficacy, supporting dose optimization efforts aligned with FDA Project Optimus. Grateful to my coauthors for their contributions to this work. @NagashreeSeeth1 @DivyaReddyMD @KRASKickers #KRAS #ProjectOptimus #LCSM ascopubs.org/doi/10.1200/OP-…

It was a privilege to present our work on recurrence in KRAS-mutant LUAD and receive thoughtful feedback from faculty. Our findings highlight an association between KRAS G12C, oxidative phosphorylation activity, and recurrence after resection. #TexasLung.

We're thrilled to announce the winners of the #TexasLung26 poster competition whose outstanding abstracts highlight important research shaping the future of lung cancer care. Join them at the poster session & welcome reception on April 9, 2026, in Austin, TX—this is where the future of lung cancer innovation comes to life! Congratulations to @JackieAredoMD, Zhaohui Arter, @yajur_arya, Wint Aung, @RobertoBoreaMD, @KCargillMDPhD, @DivyaReddyMD, @GraceHaMD, Pragya Jain, John Nawrocki, Max Schuessler, Xin Sun, Lauryn Tu, and Alessandra Vaccaro. na2.hubs.ly/H037ZVS0

We’re excited to announce the winners of the #NashvilleHeme26 Poster Competition! 🏅 Congratulations to Drs. @amishagupta2012, @DivyaReddyMD, Anthony Corsi, Matthew Gromowsky, @KellyMezaMD, Phyu Naing, Neha Puttagunta, @RahulShahK, Jessica Shostak, @rahul2u, Chidiebube Ugwu, and Graham Wehmeyer. Join them at the Poster Session & Welcome Reception, Feb. 26 in Nashville, TN at the 2-Day CE conference. Register today! na2.hubs.ly/H02MZfR0 👏👏#CME.

A VERY applicable case presented by THE AMAZING @NagashreeSeeth1 of discovering Met amp. A reminder to 👀 for MET and HER IHC on all our patients. We have approvals for these with TELISO-V and TDX-D #NYL25 @gotoPER @NorthwellHealth

Excited to attend my 1st #ASCOQLTY25 with @ConquerCancerFd Merit Award! Sharing our⚡️QI project expediting NGS testing for hospitalized patients with new NSCLC! Strong showing from @NorthwellHealth! @NagashreeSeeth1 @DivyaReddyMD @OanaCRosca @dr_nehas @WilliamChenMD #lcsm

Thrilled to present our work, “Prognostic Impact of TP53 Co-Mutations with EGFR vs KRAS in Advanced NSCLC: A cBioPortal Analysis,” at #WCLC2025 in Barcelona! Huge thanks to my amazing mentor! @NagashreeSeeth1 @IASLC @Arthur_Aung @NorthwellHealth

My amazing fellow, @DivyaReddyMD is headed to Barcelona to present her poster #WCLC25 @IASLC ‘Prognostic Impact of TP53 Co-Mutations with EGFR vs KRAS in Advanced Non-Small Cell Lung Cancer: A cBioPortal Analysis’. Pls come by on Mondayto check it out!!💙

So grateful to the @OncLive team for helping us host the first fellows forum at #ILCC2025 We planned it in several weeks and it was a great opportunity for fellows to learn from global faculty Drs. @TonyMok9 and @peters_solange

Thanks to Dr. @NagashreeSeeth1 for the invitation to @NorthwellHealth to discuss #SCLC advances with a look to the future!

Northwell heme/onc fellows, @DivyaReddyMD, @mneuman96g were unable to attend #WCLC2024 but I am so proud of their work and dedication to lung cancer research.

Delighted to share our latest piece on adrenocortical carcinoma 🗞️✅ ⭐️It was a true pleasure working with the amazing @DivyaReddyMD @MacdougallKira who are also SIUH comrades 🗽 @WinshipAtEmory @bilenma @virajmaster doi.org/10.1093/oncolo/oyae0…

Seen in the hospital: Perception from a patient.

Today's decision is a major step backward for public health. Reproductive health decisions – like all health decisions – should be made by patients and their health care providers. 1/7

Wow officially a PGY3!! 🎉 #medtwitter #internalmedicine

Dr Madala Ravikrishna of Tata Memorial discusses a study of 15,000 pts in India. Accessiblty of immunotherapy is below 3% in India Pts with head and neck cancers, those in private category and male gender had higher access, with accessibility improving over time. #ASCO22 #LCSM

We need cancer care and treatment that all patients worldwide can afford and have access to.

Sunday brunch on this rainy day in NYC

Standing ovation 👏👏👏 for results of DESTINY-Breast04. This will change practice for 50% of patients with metastatic breast cancer. This is why we all went into this field. #bcsm #ASCO22